Sarepta (SRPT) Says Eteplirsen Met Primary Endpoint in Phase IIb
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Wedbush Lifts Target on Sarepta Therapeutic (SRPT) to $70, Drug Could Sell for $300-$400K/year
October 4, 2012 3:50 PM EDTIn a note late Wednesday, Wedbush substantially raised its price target Outperform-rated Sarepta Therapeutic (NASDAQ: SRPT) from $26 to $70 following positive results from their Phase IIb extension trial of eteplirsen for Duchenne muscular dystrophy.
Some highlights from the report:
"Importantly, boys... More
